(firstQuint)A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS).

 This is a randomized open-label Phase 2 efficacy and safety study of two (2) subcutaneous (SQ) dosing schedules of decitabine in subjects with Low or Intermediate 1 Risk MDS.

 This study will be conducted in up to 6 study centers in the United States.

 The primary efficacy outcome is the overall improvement rate.

 These two doses will be administered subcutaneously.

 The probability that one schedule is superior to the other will be estimated, and the level of toxicity for each schedule will also be evaluated.

.

 A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)@highlight

The purpose of this study is to determine the effectiveness and safety of two different dose schedules of DACOGEN(R) (decitabine) for Injection in patients with Myelodysplastic Syndromes (MDS).

